Home About CDC Press Room Funding A-Z Index Centers, Institute & Offices Training & Employment Contact Us
CDC Centers for Disease Control and Prevention Home Page
_
_  
Search: 
 
_
Health & Safety TopicsPublications & ProductsData & StatisticsConferences & Events
_
Rocky Mountain Spotted Fever
Rocky Mountain Spotted Fever Home > Treatment

Treatment

Appropriate antibiotic treatment should be initiated immediately when there is a suspicion of Rocky Mountain spotted fever on the basis of clinical and epidemiologic findings. Treatment should not be delayed until laboratory confirmation is obtained.

If the patient is treated within the first 4-5 days of the disease, fever generally subsides within 24-72 hours after treatment with an appropriate antibiotic (usually in the tetracycline class). In fact, failure to respond to a tetracycline antibiotic argues against a diagnosis of RMSF. Severely ill patients may require longer periods before their fever resolves, especially if they have experienced damage to multiple organ systems. Preventive therapy in non-ill patients who have had recent tick bites is not recommended and may, in fact, only delay the onset of disease.

Doxycycline (100 mg every 12 hours for adults or 4 mg/kg body weight per day in two divided doses for children under 45 kg [100 lbs]) is the drug of choice for patients with Rocky Mountain spotted fever. Therapy is continued for at least 3 days after fever subsides and until there is unequivocal evidence of clinical improvement, generally for a minimum total course of 5 to 10 days. Severe or complicated disease may require longer treatment courses. Doxycycline is also the preferred drug for patients with ehrlichiosis, another tick-transmitted infection with signs and symptoms that may resemble Rocky Mountain spotted fever.

Tetracyclines are usually not the preferred drug for use in pregnant women because of risks associated with malformation of teeth and bones in unborn children. Chloramphenicol is an alternative drug that can be used to treat Rocky Mountain spotted fever; however, this drug may be associated with a wide range of side effects and may require careful monitoring of blood levels.

Date last reviewed: 05/20/2005

_
blue divider
Program Contents
bullet Home
bullet Overview
bullet Questions and Answers
bullet The Organism
bullet Natural History
bullet Epidemiology
bullet Signs and Symptoms
bullet Laboratory Detection
bullet Treatment
bullet Prevention and Control
bullet References and Resources
bullet Glossary
bullet Case Report Form Adobe Acrobat Reader
(1.2 MB, 3 pages)
Tick-Borne Rickettsial Disease Case Report. Use for reporting cases of RMS, HME, and HGE.
blue divider
Contact Info

1600 Clifton Road, MS-G13
Atlanta, GA 30033
Phone: +1(404) 639-3534
+1(800) 311-3435

grey divider
 
 
    Home   |   Policies and Regulations   |   Disclaimer   |   e-Government   |  FOIA   |  Contact Us  
Safer, Healthier People USAGovDHHS Department of Health
and Human Services
Centers for Disease Control and Prevention,1600 Clifton Rd, Atlanta, GA 30333, U.S.A
Tel: (404) 639-3311 / Public Inquiries: (404) 639-3534 / (800) 311-3435